Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

789.32 +34.32 (+4.55%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Wall Street On Edge Ahead Of Fed Decision, Spotlight Falls On Amazon And AMD Earnings: Analyst Says Stocks Survive 'Fragility Test' As April Ends
U.S. stocks appear to be on the back foot early on Tuesday, with index futures trading modestly lower in early pre-market activity. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Markets Up On Tesla, Q1 Earnings; Q1 Beats After The Bell
Market indices finished in the green across the board this Monday. It’s now the third straight day higher going back to Thursday of last week, and recovered from a quick drop into the red (mostly)... 
Via Talk Markets
Here's How Much Stock Eli Lilly Repurchased in 2023
Hint: It probably wasn't as much as you might imagine given the company's immensity. 
Via The Motley Fool
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly Just Announced More Good News: Time to Buy?
There's no stopping this high-flying biotech. 
Via The Motley Fool
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q1 Earnings Report
Eli Lilly investors may be eyeing potential gains from dividends. The company is currently offering an annual dividend yield of 0.71%. 
Via Benzinga
Nasdaq Bull Market: Here's the Best Investing Move You Can Make Right Now
Many technology stocks are soaring, and you may be wondering if they've gotten too expensive. 
Via The Motley Fool
Is Viking Therapeutics Incredibly Undervalued?
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound. 
Via The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence. 
Via The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications. 
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks. 
Via The Motley Fool
MarketBeat Week in Review – 4/22 - 4/26
Investors continue to look for clarity as tech earnings sent stocks higher to end the week, even as investors hope for rate cuts fade as inflation rises 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
SPDR ETF Report For Friday, April 26
Via Talk Markets
Topics ETFs
Jim Cramer Weighs In Ahead Of Apple, Amazon, Eli Lilly Earnings: 'We Have To Run Such A Ridiculous Gauntlet Next Week'
Jim Cramer has highlighted upcoming significant events for investors, including earnings from major companies like Apple and Amazon, and key economic indicators such as the Federal Reserve meeting and... 
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
ResMed is the biggest maker of CPAPs in the U.S., and says the growing popularity of weight-loss drugs could help diagnosis rates. 
Via Investor's Business Daily
Dividend Legends: 3 Stocks With Over 100 Years of Payouts
Dividend payers are companies that have stood the test of time and these dividend stocks with 100+ years of payouts lead them all. 
Via InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
Don’t Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List
These three large-cap blue-chip growth stocks are certainly worth considering as core portfolio holdings in this current environment. 
Via InvestorPlace
Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
Explore the dynamics of money-maker stocks in 2024, which are fueled by AI advancements and robust economic growth. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could... 
Via Benzinga
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Lilly recently announced news that could solve a big problem. 
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
REITs Q1 Earnings Begin On Solid Note
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Eli Lilly expands its global manufacturing network with FDA-approved facility acquisition in Pleasant Prairie, Wisconsin. Boosting production to meet growing demand for medicines, including GLP-1... 
Via Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
After performing strongly since the start of the year, it's time to sell these stocks due for a pullback before they reverse course. 
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits. 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.